ViroGates A/S (VIRO) - Net Assets

Latest as of September 2025: Dkr2.83 Million DKK ≈ $443.56K USD

Based on the latest financial reports, ViroGates A/S (VIRO) has net assets worth Dkr2.83 Million DKK (≈ $443.56K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr14.21 Million ≈ $2.22 Million USD) and total liabilities (Dkr11.38 Million ≈ $1.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does ViroGates A/S carry for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Dkr2.83 Million
% of Total Assets	19.95%
Annual Growth Rate	-3.14%
5-Year Change	-65.53%
10-Year Change	N/A
Growth Volatility	618.16

ViroGates A/S - Net Assets Trend (2015–2024)

This chart illustrates how ViroGates A/S's net assets have evolved over time, based on quarterly financial data. Also explore VIRO total asset value for the complete picture of this company's asset base.

Annual Net Assets for ViroGates A/S (2015–2024)

The table below shows the annual net assets of ViroGates A/S from 2015 to 2024. For live valuation and market cap data, see VIRO company net worth.

Year	Net Assets	Change
2024-12-31	Dkr10.79 Million ≈ $1.69 Million	-36.53%
2023-12-31	Dkr17.01 Million ≈ $2.66 Million	+5.71%
2022-12-31	Dkr16.09 Million ≈ $2.52 Million	-2.06%
2021-12-31	Dkr16.43 Million ≈ $2.57 Million	-47.54%
2020-12-31	Dkr31.31 Million ≈ $4.90 Million	-25.82%
2019-12-31	Dkr42.22 Million ≈ $6.60 Million	-30.81%
2018-12-31	Dkr61.01 Million ≈ $9.55 Million	+1935.74%
2017-12-31	Dkr3.00 Million ≈ $468.90K	-66.64%
2016-12-31	Dkr8.98 Million ≈ $1.41 Million	-37.55%
2015-12-31	Dkr14.39 Million ≈ $2.25 Million	--

Equity Component Analysis

This analysis shows how different components contribute to ViroGates A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 74.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	Dkr3.06 Million	28.33%
Common Stock	Dkr7.74 Million	71.67%
Total Equity	Dkr10.79 Million	100.00%

ViroGates A/S Competitors by Market Cap

The table below lists competitors of ViroGates A/S ranked by their market capitalization.

Company	Market Cap
Overactive Media Corp V:OAM	$15.99 Million
Javelin Minerals Ltd AU:JAV	$15.99 Million
Turbo Mech Bhd KLSE:5167	$16.00 Million
In8bio Inc NASDAQ:INAB	$16.00 Million
Nusantara Almazia JK:NZIA	$15.97 Million
Marwynn Holdings, Inc. Common stock NASDAQ:MWYN	$15.96 Million
Elicera Therapeutics AB ST:ELIC	$15.96 Million
Vinpai SAS PA:ALVIN	$15.94 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ViroGates A/S's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 17,007,000 to 10,795,000, a change of -6,212,000 (-36.5%).
Net loss of 14,345,000 reduced equity.
New share issuances of 8,133,000 increased equity.
Other comprehensive income increased equity by 1,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Dkr-14.35 Million	-132.89%
Share Issuances	Dkr8.13 Million	+75.34%
Other Comprehensive Income	Dkr1.00K	+0.01%
Other Changes	Dkr-1.00K	-0.01%
Total Change	Dkr-	-36.53%

Book Value vs Market Value Analysis

This analysis compares ViroGates A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 6.79x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 2.19x to 6.79x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2015-12-31	Dkr5.01	Dkr11.00	x
2016-12-31	Dkr3.13	Dkr11.00	x
2017-12-31	Dkr1.23	Dkr11.00	x
2018-12-31	Dkr20.59	Dkr11.00	x
2019-12-31	Dkr10.74	Dkr11.00	x
2020-12-31	Dkr7.83	Dkr11.00	x
2021-12-31	Dkr4.02	Dkr11.00	x
2022-12-31	Dkr3.81	Dkr11.00	x
2023-12-31	Dkr4.91	Dkr11.00	x
2024-12-31	Dkr1.62	Dkr11.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently ViroGates A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -132.89%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -292.93%
• Asset Turnover: 0.28x
• Equity Multiplier: 1.64x
Recent ROE (-132.89%) is below the historical average (-79.19%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	-28.29%	-113.28%	0.21x	1.21x	Dkr-5.51 Million
2016	-60.13%	-146.58%	0.31x	1.34x	Dkr-6.30 Million
2017	-199.77%	-245.27%	0.49x	1.66x	Dkr-6.29 Million
2018	-27.84%	-512.24%	0.05x	1.04x	Dkr-23.09 Million
2019	-44.53%	-524.76%	0.08x	1.07x	Dkr-23.02 Million
2020	-59.83%	-349.94%	0.14x	1.22x	Dkr-21.87 Million
2021	-107.53%	-230.71%	0.38x	1.23x	Dkr-19.31 Million
2022	-59.96%	-63.47%	0.87x	1.09x	Dkr-11.25 Million
2023	-71.12%	-173.12%	0.28x	1.44x	Dkr-13.80 Million
2024	-132.89%	-292.93%	0.28x	1.64x	Dkr-15.42 Million

Industry Comparison

This section compares ViroGates A/S's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $1,209,409,454
Average return on equity (ROE) among peers: 36.94%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
ViroGates A/S (VIRO)	Dkr2.83 Million	-28.29%	4.01x	$15.97 Million
Ambu A/S (AMBU-B)	$294.12 Million	8.84%	0.89x	$2.44 Billion
ChemoMetec A/S (CHEMM)	$73.01 Million	24.95%	0.56x	$925.73 Million
Demant A/S (DEMANT)	$756.47 Million	104.51%	2.82x	$7.91 Billion
GN Store Nord (GN)	$4.85 Billion	29.99%	2.44x	$2.13 Billion
Scandinavian Medical Solutions AS (SMSMED)	$74.45 Million	16.42%	1.20x	$12.52 Million

About ViroGates A/S

CO:VIRO Denmark Medical Devices

Market Cap

$15.97 Million

Dkr102.10 Million DKK

Market Cap Rank

#25812 Global

#117 in Denmark

Share Price

Dkr11.00

Change (1 day)

+4.76%

52-Week Range

Dkr7.80 - Dkr17.40

All Time High

Dkr238.00